Effect of drugs on after-nystagmus induced by lateral vestibular nucleus stimulation.
D000818:Animals; D002415:Cats; D002746:Chlorpromazine / Q000627:therapeutic use; D003501:Cyclizine / Q000627:therapeutic use; D004111:Dimenhydrinate / Q000627:therapeutic use; D004155:Diphenhydramine / Q000627:therapeutic use; D004558:Electric Stimulation; D006919:Hydroxyzine / Q000627:therapeutic use; D008012:Lidocaine / Q000627:therapeutic use*; D008468:Meclizine; D009759:Nystagmus, Pathologic / Q000188:drug therapy*; D010424:Pentobarbital / Q000627:therapeutic use*; D010640:Phenothiazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use; D011346:Prochlorperazine / Q000627:therapeutic use; D011398:Promethazine / Q000627:therapeutic use; D014309:Tripelennamine / Q000627:therapeutic use; D014726:Vestibular Nuclei / Q000502:physiology*
D010640:Phenothiazines; D010879:Piperazines; D006919:Hydroxyzine; D014309:Tripelennamine; D008468:Meclizine; D004155:Diphenhydramine; D008012:Lidocaine; D011398:Promethazine; D010424:Pentobarbital; D004111:Dimenhydrinate; D003501:Cyclizine; D002746:Chlorpromazine; D011346:Prochlorperazine